[HTML][HTML] The impact of early molecular response in event free survival in patients with chronic myeloid leukemia treated with imatinib
L Fogliatto, MEZ Capra, M Shaan, TV Costa… - Blood, 2014 - Elsevier
Background Monitoring response to TKI therapy is one of the key management strategies of
chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is …
chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is …
[HTML][HTML] Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.
D Verma, HM Kantarjian, J Shan, S O'Brien, A Verma… - Blood, 2009 - Elsevier
Abstract Abstract 505 Background: Therapy with imatinib and other tyrosine kinase inhibitors
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …
The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid …
R Hehlmann, B Hanfstein, MC Müller, P Erben… - 2012 - ascopubs.org
6510 Background: In the face of competing first line treatment options for CML early
prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise …
prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise …
[HTML][HTML] Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase chronic myelogenous leukemia–an …
MC Müller, B Hanfstein, P Erben, S Schnittger… - Blood, 2008 - Elsevier
The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …
[HTML][HTML] No Differences in outcomes between patients achieving early molecular response at 3 months and those achieving optimal response at 6 or 12 months in …
MC Kuo, TY Chen, MC Wang, Y Yang, SP Yeh… - Blood, 2014 - Elsevier
Abstract Introduction and Aims: Recent reports demonstrated the importance of early
molecular response (EMR) in chronic myeloid leukemia (CML) treated with tyrosine kinase …
molecular response (EMR) in chronic myeloid leukemia (CML) treated with tyrosine kinase …
[HTML][HTML] The impact of cytogenetic response at 6 months of therapy in global survival of patients with chronic myeloid leukemia treated with imatinib in the south of …
L Fogliatto, M Capra, M Schaan, MS Fernandes… - Blood, 2012 - Elsevier
Abstract Abstract 4453 Background Treatment of chronic myeloid leukemia with imatinib
leads to disease remission in a majority of patient, but in some patients (pts) controlling the …
leads to disease remission in a majority of patient, but in some patients (pts) controlling the …
The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for …
FE Nicolini, S Hayette, L Gilis, M Etienne, E Gadolet… - 2010 - ashpublications.org
Abstract 3407 It has been demonstrated that obtaining early complete cytogenetic response
(CCyR) in chronic phase (CP) chronic myeloid leukemia (CML) represents a guarantee for a …
(CCyR) in chronic phase (CP) chronic myeloid leukemia (CML) represents a guarantee for a …
[HTML][HTML] Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic …
B Hanfstein, MC Müller, P Erben, S Schnittger… - Blood, 2010 - Elsevier
Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …
treatment has been observed in a substantial proportion of CML patients and has been …
Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).
E Aoki, H Kantarjian, S O'Brien, MB Rios, F Ravandi… - 2005 - ashpublications.org
Imatinib has remarkable activity in CML in all phases, with high rates of hematologic and
cytogenetic response. However, in AP and BP responses are frequently less than complete …
cytogenetic response. However, in AP and BP responses are frequently less than complete …
[HTML][HTML] Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on …
G Etienne, NE Nicolini, S Dulucq, A Schmitt, S Hayette… - Blood, 2012 - Elsevier
Abstract Abstract 3754 Background Imatinib (IM) has dramatically improved the prognosis of
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …